Summary
70 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 130% a year over the last 3 years.
- Out of every 100 SEK of revenue, 30 SEK is left as net profit.
- It holds more cash than debt: 4.07B kr against 108.4M kr.
- Analysts expect revenue to grow by 27% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 53.9 SEK for 1 SEK of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (SEK)
Diluted EPS (SEK)
- Analyst estimate
Revenue grew by 46% a year over 5 years. Over the last 3 years it grew by 33% a year. For the next fiscal year analysts expect revenue to grow by 27%. Earnings per share grew by 130% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 SEK of revenue goes
- Cost of sales 7.5 SEK
- Research and development 21 SEK
- Sales and administration 35 SEK
- Taxes and other 6.4 SEK
- Net profit 30 SEK
Net profit, industry median (Biotechnology) -7.3 SEK
Out of every 100 SEK of revenue, 30 SEK is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.